Galectins in the tumor endothelium: Opportunities for combined cancer therapy

Blood

Volumn 110, Issue 8, 2007, Pages 2819-2827

  Thijssen, Victor L J L ^a   Poirier, Françoise ^b   Baum, Linda G ^c   Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CNRS   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 1 ANTIBODY; GALECTIN 3; PECTIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER THERAPY; CARCINOGENESIS; ENDOTHELIUM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TUMOR VASCULARIZATION;

EID: 35549003245     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-077792     Document Type: Review

References (102)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:237-268.
3. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A. 1993;90:8996-9000.
4. Brandwijk RJ, Griffioen AW, Thijssen VL. Targeted gene-delivery strategies for angiostatic cancer treatment. Trends Mol Med. 2007;13:200-209.
5. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436-446.
6. van Beijnum JR, Griffioen AW. In silico analysis of angiogenesis associated gene expression identi-fies angiogenic stage related profiles. Biochim Biophys Acta. 2005;1755:121-134.
7. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006;103:15975-15980.
8. Bidon-Wagner N, Le Pennec JP. Human galectin-8 isoforms and cancer. Glycoconj J. 2004;19:557-563.
9. Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer. 2005;92:1188-1192.
10. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis. 2005;26:309-318.
11. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002;1572:209-231.
12. Seelenmeyer C, Wegehingel S, Tews I, Kunzler M, Aebi M, Nickel W. Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1. J Cell Biol. 2005;171:373-381.
13. Hughes RC. Galectins as modulators of cell adhesion. Biochimie. 2001;83:667-676.
14. Leffler H. Galectins structure and function: a synopsis. Results Probl Cell Differ. 2001;33:57-83.
15. Houzelstein D, Goncalves IR, Fadden AJ, et al. Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol. 2004;21:1177-1187.
16. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature. 1995;378:736-739.
17. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res. 2001;29:3595-3602.
18. Scott K, Weinberg C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J. 2004;19:467-477.
19. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29-41.
20. van den Brule F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J. 2004;19:537-542.
21. Huflejt ME, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J. 2004;20:247-255.
22. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006;16:137R-157R.
23. Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. Galectin-1 receptors in different cell types. J Biomed Sci. 2005;12:13-29.
24. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med. 1998;76:402-412.
25. Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL. Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconj J. 1994;11:462-468.
26. Baum LG, Seilhamer JJ, Pang M, Levine WB, Beynon D, Berliner JA. Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J. 1995;12:63-68.
27. Lame MW, Jones AD, Wilson DW, Dunston SK, Segall HJ. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem. 2000;275:29091-29099.
28. Lame MW, Jones AD, Wilson DW, Segall HJ. Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells. Proteomics. 2005;5:4398-4413.
29. Rabinovich GA, Cumashi A, Bianco GA, et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology. 2006;16:210-220.
30. He J, Baum LG. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest. 2006;86:578-590.
31. Clausse N, van den Brule F, Waltregny D, Garnier F, Castronovo V. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis. 1999;3:317-325.
32. Dumic J, Dabelic S, Flogel M. Galectin-3: An open-ended story. Biochim Biophys Acta. 2006;1760:616-635.
33. Massa SM, Cooper DN, Leffler H, Barondes SH. L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity. Biochemistry. 1993;32:260-267.
34. Ahmad N, Gabius HJ, Andre S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem. 2004;279:10841-10847.
35. Nieminen J, Kuno A, Hirabayashi J, Sato S. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem. 2006;282:1374-1383.
36. Fukushi J, Makagiansar IT, Stallcup WB. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell. 2004;15:3580-3590.
37. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis. 2005;22:11-24.
38. Ryschich E, Lizdenis P, Ittrich C, et al. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 2006;66:198-211.
39. Glinskii OV, Turk JR, Pienta KJ, Huxley VH, Glinsky VV. Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. J Physiol. 2004;554:89-99.
40. Glinsky VV, Glinsky GV, Glinskii OV, et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003;63:3805-3811.
41. Gil CD, La M, Perretti M, Oliani SM. Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int. 2006;30:338-344.
42. Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem. 1997;272:6416-6422.
43. Matsumoto R, Matsumoto H, Seki M, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem. 1998;273:16976-16984.
44. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J. 2004;19:491-498.
45. Irie A, Yamauchi A, Kontani K, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 2005;11:2962-2968.
46. Pioche-Durieu C, Keryer C, Souquere S, et al. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol. 79:13326-13337, 2005.
47. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245-1252.
48. Spitzenberger F, Graessler J, Schroeder HE. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie. 2001;83:851-862.
49. Imaizumi T, Kumagai M, Sasaki N, et al. Interferon-γ stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol. 2002;72:486-491.
50. Warke RV, Xhaja K, Martin KJ, et al. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J Virol. 2003;77:11822-11832.
51. Ishikawa A, Imaizumi T, Yoshida H, et al. Double-stranded RNA enhances the expression of galectin-9 in vascular endothelial cells. Immunol Cell Biol. 2004;82:410-414.
52. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J. 2004;19:575-581.
53. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 1996;88:667-673.
54. Molema G, Griffioen AW. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today. 1998;19:392-394.
55. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003;63:2322-2329.
56. Rabinovich GA, Toscano MA, Ilarregui JM, Rubinstein N. Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj J. 2004;19:565-573.
57. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell. 2004;5:241-251.
58. Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005;23:8932-8941.
59. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of EBV-specific T-cell immunity in classical Hodgkin's Lymphoma. Blood. Prepublished online April 16, 2007, as DOI 10.1182/blood-2007-01-066100.
60. Valenzuela HF, Pace KE, Cabrera PV, et al. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res. 2007;67:6155-6162.
61. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol. 2006;168:1666-1675.
62. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol. 2002;168:1813-1822.
63. van de Weyer PS, Muehlfeit M, Klose C, Bonventre JV, Walz G, Kuehn EW. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun. 2006;351:571-576.
64. Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med. 1997;185:1851-1858.
65. He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem. 2004;279:4705-4712.
66. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest. 1997;99:2452-2461.
67. Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003;63:8302-8311.
68. Dai SY, Nakagawa R, Itoh A, et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol. 2005;175:2974-2981.
69. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature. 2001;409:733-739.
70. Elola MT, Wolfenstein-Todel C, Troncoso P, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64:1679-1700.
71. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2004;19:543-549.
72. Khaldoyanidi SK, Glinsky VV, Sikora L, et al. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem. 2003;278:4127-4134.
73. Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res. 2000;60:2584-2588.
74. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 1998;90:118-123.
75. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 1987;236:582-585.
76. Kuzbicki L, Gajo B, Chwirot BW. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res. 2006;16:235-243.
77. Sarafian V, Jadot M, Foidart JM, et al. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int J Cancer. 1998;75:105-111.
78. Inohara H, Raz A. Identification of human melanoma cellular and secreted ligands for galectin-3. Biochem Biophys Res Commun. 1994;201:1366-1375.
79. Yu LG. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J. Prepublished on April 25, 2007, as DOI 10.1007/s10719-007-9034-3.
80. Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell-endothelial adhesion. J Biol Chem. 2007;282:773-781.
81. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005;7:522-527.
82. Saitoh O, Wang WC, Lotan R, Fukuda M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 1992;267:5700-5711.
83. Sawada R, Tsuboi S, Fukuda M. Differential Eselectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 1994;269:1425-1431.
84. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
85. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis. Am J Pathol. 2000;156:899-909.
86. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94:1854-1862.
87. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev. 2005;16:535-548.
88. Weinstein BM. Vessels and nerves: marching to the same tune. Cell. 2005;120:299-302.
89. McGraw J, Gaudet AD, Oschipok LW, et al. Altered primary afferent anatomy and reduced thermal sensitivity in mice lacking galectin-1. Pain. 2005;114:7-18.
90. McGraw J, McPhail LT, Oschipok LW, et al. Galectin-1 in regenerating motoneurons. Eur J Neurosci. 2004;20:2872-2880.
91. Fukaya K, Hasegawa M, Mashitani T, et al. Oxidized galectin-1 stimulates the migration of Schwann cells from both proximal and distal stumps of transected nerves and promotes axonal regeneration after peripheral nerve injury. J Neuropathol Exp Neurol. 2003;62:162-172.
92. Puche AC, Poirier F, Hair M, Bartlett PF, Key B. Role of galectin-1 in the developing mouse olfactory system. Dev Biol. 1996;179:274-287.
93. Rusciano D, Lorenzoni P, Burger MM. Specific growth stimulation in the absence of specific cellular adhesion in lung colonization by retinoicacid-treated F9 teratocarcinoma cells. Int J Cancer. 1992;52:471-477.
94. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87:348-353.
95. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J. 2001;354:233-242.
96. van der Schaft DW, Dings RP, de Lussanet QG, et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 2002;16:1991-1993.
97. Akerman ME, Pilch J, Peters D, Ruoslahti E. Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A. 2005;102:2040-2045.
98. Brandwijk RJ, Nesmelova I, Dings RP, Mayo KH, Thijssen VL, Griffioen AW. Cloning an artificial gene encoding angiostatic anginex: from designed peptide to functional recombinant protein. Biochem Biophys Res Commun. 2005;333:1261-1268.
99. Pilch J, Franzin CM, Knowles LM, Ferrer FJ, Marassi FM, Ruoslahti E. The anti-angiogenic peptide anginex disrupts the cell membrane. J Mol Biol. 2006;356:876-885.
100. Mulder WJ, Strijkers GJ, Griffioen AW, et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem. 2004;15:799-806.
101. Brandwijk RJ, Mulder WJ, Nicolay K, Mayo KH, Thijssen VL, Griffioen AW. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem. 2007;18:785-790.
102. Andre S, Maljaars CE, Halkes KM, Gabius HJ, Kamerling JP. Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett. 2007;17:793-798.